近年來(lái)，腫瘤的免疫治療已成為繼傳統(tǒng)手術(shù)、放療、化療、內(nèi)分泌治療和靶向藥物治療手段之后新的治療方法，尤其以程序性死亡受體1（PD-1）/程序性死亡配體1（PD-L1）位靶點(diǎn)的免疫檢查點(diǎn)抑制治療使得非小細(xì)胞肺癌、黑色素瘤等惡性實(shí)體腫瘤患者獲得了有效持久的臨床獲益。PD-L1的檢測(cè)是免疫檢查點(diǎn)抑制劑治療的關(guān)鍵環(huán)節(jié)，但在乳腺癌中的其檢測(cè)方法和判定標(biāo)準(zhǔn)尚未統(tǒng)一。就PD-L1的檢測(cè)方法以及其在乳腺癌各分子分型中的表達(dá)進(jìn)行綜述。

In recent years, tumor immunotherapy has become a new anti-tumor therapy after surgery, radiotherapy, chemotherapy, endocrinotherapy, and targeted drug therapy. In particular, many of patients with non-small cell lung cancer, melanoma and other malignant solid tumors have gained effective and lasting clinical benefits from the immune-checkpoint inhibition therapy which targeting for PD-1/PD-L1. The detection of PD-L1 is a key link in the treatment of immune checkpoint inhibitors, but its detection methods and criteria in breast cancer have not been unified. This paper reviewed the detection methods of PD-L1 and its expression in subtypes of breast cancer.

R966

國(guó)家自然科學(xué)基金資助項(xiàng)目（81903856）